Stock MRSN MERSANA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
2.31 USD +5.00% Intraday chart for Mersana Therapeutics, Inc. -1.70% -0.43%
May. 09 Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mersana Therapeutics Gears Up for Milestones in Cancer Drug Trials
Mersana Therapeutics, Inc. Announces Business Updates
Mersana Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Mersana Therapeutics, Inc. Announces FDA Has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
Mersana Therapeutics Names Martin Huber as Chief Executive
Mersana Therapeutics Announces Management Changes
Mersana Therapeutics, Inc. Announces Chief Executive Officer Changes
Mersana Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Mersana Therapeutics Shares Plummet After Analyst Downgrades, Ovarian-Cancer Therapy Failure
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Sector Update: Health Care
Mersana Therapeutics Says Trial of Ovarian Cancer Treatment Misses Primary Endpoint; Shares Plunge
Top Premarket Decliners
Mersana Therapeutics, Inc. Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
BB Biotech dimezza la perdita trimestrale e dice addio a Piazza Affari
Top Midday Decliners
Mersana Therapeutics Says FDA Issues Partial Clinical Hold on Enrollment in Ovarian Cancer Drug Trials; Shares Plunge
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRSN Stock
  4. News Mersana Therapeutics, Inc.
  5. Other languages